Autopsy report · NCT06552000

Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

“Sponsor deprioritized the study and made the choice to close the study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University of Texas Southwestern Medical Center

Sponsor type

University, hospital or other

Conditions

NSCLC; Non Small Cell Lung Cancer

Interventions

NovoTTF-200T System

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
  “Sponsor Decision to close study” (82% match in meaning)
• Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
  “Sponsor decision to terminate the study” (82% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (81% match in meaning)
• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
  “Study sponsor decided to close study.” (80% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.